Early intervention of large-dose somatostatin for the prevention of pancreatic pseudocyst in severe acute pacreatitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000579

Enrollment

Unknown

Registered

2009-11-02

Start date

2009-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe acute pancreatitis

Interventions

B:Large dosage of somatostatin 500ug/hr for 7-14 day

A:Large dosage of somatostatin 500ug/hr for 7-14 day

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 75 years old; 2. Diagnosed with severe acute pancreatitis (APACHEII>=8; Ranson>=3; or CT Balthazar: D or E degree); 3. The duration of the disease<= 72 hours (begin with the onset of abdominal pain); 4. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Diagnosed with mild acute pancreatitis or fulminant pancreatitis; 2. Alergic to or with contraindications for somatostatin; 3. With malignant tumors; 4. Pregnant or breast-feeding women; 5. Participate in other clinical trials within 12 weeks before the study; 6. Individuals related to this study, such as trial designers, executors and statistician.

Design outcomes

Primary

Measure	Time frame
The incidence of pancreatic pseudocyst;	—

Secondary

Measure	Time frame
The percentage of patients needing surgical intervention;Mortality;	—

Countries

China

Contacts

Public ContactZhaoshen Li

xianbaozhan@yahoo.com+86 021 81873241

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026